Photo taken from Shushan Hovsepyan/LinkedIn
Jan 20, 2024, 17:23
Shushan Hovsepyan: Have you checked the MASCC/ESMO update on CT-induced nausea/vomiting?
Shushan Hovsepyan, Clinical Research Coordinator at the Yeolyan Hematology and Oncology Center, shared on X/Twitter:
”Have you checked the MASCC/ESMO update on CT-induced nausea/vomiting?
- High-dose CT and stem-cell transplant = 5-HT3 antagonist+dexa+aprepitant,
- Multi-day Cisplatin= 5-HT3antagonist+dexa +aprepitant +olanzapine,
- Breakthrough N/V=single dose olanzapine 3day.”
Read further.
Source: Shushan Hovsepyan/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19